ReviewClinical kidney journal2023
Alleviating symptoms in patients undergoing long-term hemodialysis: a focus on chronic kidney disease-associated pruritus.
Review in Clinical kidney journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Therapeutic effects of acupuncture therapy for kidney function and common symptoms in patients with chronic kidney disease: a systematic review and meta-analysis.Renal failure · 2024Pooled it
- Article
- Article
- Real-world effectiveness of difelikefalin for CKD-aP in UK haemodialysis: a single-centre experience.Clinical kidney journal · 2026Article
- Association of Chronic Kidney Disease-Associated Pruritus With the Sleep Disturbance, Depression, Pain, Anxiety, and Low Energy/Fatigue Symptom Cluster: A Retrospective Cohort Study.Kidney medicine · 2026Article
- Chronic kidney disease associated pruritus and healthcare resource utilization in European hemodialysis patients: results from an electronic patient-reported outcome survey.BMC nephrology · 2025Article
- Prevalence, severity, and determinants of CKD-associated pruritus in a Swiss hemodialysis population with widespread use of hemodiafiltration: a cross-sectional study.BMC nephrology · 2025Observational
- Impact of symptom burden clusters on self-efficacy and quality of life in hemodialysis patients: a multicenter cross-sectional study.Scientific reports · 2025Article
- Real-world safety of difelikefalin for chronic kidney disease-associated pruritus: initial insights from a European managed access programme.Clinical kidney journal · 2025Article
- Difelikefalin for CKD-aP: real world evidence of efficacy and safety in Italian patients.Clinical kidney journal · 2025Article
- Meta-Analysis of Randomized Controlled Trials on Gamma-Aminobutyric Acid Analogues and Opioid-Based Therapies for CKD-Associated Pruritus.Kidney international reports · 2025Article
- Haemodiafiltration versus high-flux haemodialysis-a Consensus Statement from the EuDial Working Group of the ERA.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025Article
- Nurse's Perceptions and Roles in the Management of Chronic Kidney Disease-Associated Pruritus: A Multicentre Survey Across Europe.Journal of renal care · 2025Article
- CKD-associated pruritus in haemodialysis: a road map for diagnosis and treatment.Clinical kidney journal · 2025Review
- Quality of life and clinical data in hemodialysis patients with different degrees of pruritus.Scientific reports · 2025Observational
- Chronic kidney disease.Nature reviews. Disease primers · 2025Review
- Successful Use of Difelikefalin in Severe Chronic Kidney Disease-Associated Pruritus in a Patient With Complex Etiological Contributors: A Case Report.Case reports in nephrology · 2025Article
- Long-Term Efficacy and Tolerability of an Emollient Containing Glycerol and Paraffin for Moderate-to-Severe Uremic Xerosis: A Randomized Phase 3 Study.Dermatology and therapy · 2024Article
- Article
- Difelikefalin for pruritus associated with chronic kidney disease.Australian prescriber · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 6 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since the breakthrough of kidney replacement therapy, increases in life expectancy for patients with end-stage kidney disease have been limited. However, patients have become increasingly vocal that, although mortality and life expectancy matter to them, the quality of their life, and particularly the relief of symptoms associated with their treatment, are in many cases more important. The majority of dialysis-associated symptoms and adverse effects do not currently have any approved treatments in this patient population, with the few treatments that are available used off-label, frequently without proven efficacy, yet still potentially adding further adverse effects to patients' current symptom burden. This article will illustrate how understanding the pathophysiology of a single, particularly burdensome symptom of dialysis (chronic kidney disease-associated pruritus) resulted in the design, development and regulatory approval of a treatment for that symptom. The pathway described here can be applied to other symptoms associated with dialysis, meaning that if we cannot add years to patients' lives, we can at least add life to their remaining years.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.